Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To demonstrate that the efficacy of Secukinumab 150 mg s.c. (Secukinumab from week 0 with NSAID tapering allowed from week 4; “delayed tapering”) at Week 12 is superior to placebo based on the proportion of patients achieving an ASAS20 response.
Inclusion criteria
- Ankylosing spondylitis